Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission

(2010) N.-C. Gorin et al.   BLOOD

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

(2010) C. Bachas et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction

(2010) D. C. Taussig et al.   BLOOD

Monitoring of minimal residual disease in acute myeloid leukemia

(2010) Francesco Buccisano et al.   CURRENT OPINION IN ONCOLOGY

Assessment of minimal residual disease in acute myeloid leukemia

(2010) David Grimwade et al.   CURRENT OPINION IN ONCOLOGY

The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0

(2010) Ritsuro Suzuki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

HighEVI1Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

(2010) Stefan Gröschel et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

(2010) V H J van der Velden et al.   LEUKEMIA

Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification

(2010) W van den Ancker et al.   LEUKEMIA

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

(2009) T. M. Westers et al.   BLOOD

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features

(2009) C. Haferlach et al.   BLOOD

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology

(2009) B. Cate et al.   CURRENT DRUG TARGETS

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML

(2009) Monique Terwijn et al.   EUROPEAN JOURNAL OF CANCER

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes

(2009) N. Goardon et al.   HAEMATOLOGICA

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

(2009) M. C. Bene et al.   HAEMATOLOGICA

Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study

(2009) K. Ogata et al.   HAEMATOLOGICA

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

(2009) A. A. van de Loosdrecht et al.   HAEMATOLOGICA

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity

(2009) W Kern et al.   LEUKEMIA

Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)

(2009) Bruno C. Medeiros et al.   LEUKEMIA RESEARCH

Incidence, Sensitivity, and Specificity of Leukemia-Associated Phenotypes in Acute Myeloid Leukemia Using Specific Five-Color Multiparameter Flow Cytometry

(2008) Adhra Al-Mawali et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

(2008) María Díez-Campelo et al.   AMERICAN JOURNAL OF HEMATOLOGY

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

(2008) B. L. Scott et al.   BLOOD

Flow cytometric immunophenotyping for hematologic neoplasms

(2008) F. E. Craig et al.   BLOOD

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

(2008) M. A. Sanz et al.   BLOOD

Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals

(2008) Hans Beier Ommen et al.   BRITISH JOURNAL OF HAEMATOLOGY

The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

(2008) Adhra Al-Mawali et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

(2008) C. J. Hess et al.   HAEMATOLOGICA

A Multidimensional Classification Approach for the Automated Analysis of Flow Cytometry Data

(2008) Carlos Eduardo Pedreira et al.   IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study

(2008) F Lacombe et al.   LEUKEMIA

The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors

(2008) S Matarraz et al.   LEUKEMIA

Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

(2008) Clara Cesana et al.   LEUKEMIA RESEARCH

Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes

(2008) Chikako Satoh et al.   LEUKEMIA RESEARCH

Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome

(2007) Sabine Knipp et al.   LEUKEMIA RESEARCH

Flow cytometry in myelodysplastic syndromes: Report from a working conference

(2007) Michael R. Loken et al.   LEUKEMIA RESEARCH

The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes

(2007) I. Lorand-Metze et al.   LEUKEMIA RESEARCH

Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: Emphasis on a global evaluation and recognition of diagnostic pitfalls

(2007) Dariusz Stachurski et al.   LEUKEMIA RESEARCH